<DOC>
	<DOCNO>NCT00494221</DOCNO>
	<brief_summary>This Study two part , first part make sure combine potential new treatment , cediranib ( AZD2171 ) , standard treatment ( FOLFOX ) metastatic colorectal cancer safe . Once part complete decide safe continue Study go look efficacy two drug together . This do study two treatment option . One standard treatment alone ( FOLFOX ) + dummy cediranib ( AZD2171 ) tablets standard treatment ( FOLFOX ) + real cediranib ( AZD2171 ) tablet . Using dummy tablet mean study 'blinded ' non-one tell difference two treatment group . This kind study design do try avoid chance result might bias way . The overall aim second part study see add cediranib ( AZD2171 ) standard treatment Metastatic Colorectal Cancer ( mCRC ) , case FOLFOX , give good result . That , 's well give standard treatment alone help prevent progression mCRC .</brief_summary>
	<brief_title>A Phase I/II Study Cediranib ( AZD2171 ) Japanese Metastatic Colorectal Cancer Patients Combination With FOLFOX</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Metastatic colorectal cancer WHO performance status 01 Life expectancy 12 week longer Patient uncontrolled brain metastasis Patient inappropriate laboratory test value Patient poorly control hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Recentin</keyword>
	<keyword>Metastatic Cancer</keyword>
	<keyword>FOLFOX</keyword>
</DOC>